A landmark, evidence‑based clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma (FLC) has been released online ahead of publication in the journal Hepatology. Developed by a panel of 20 expert physicians from 15 leading cancer centers and supported by the Fibrolamellar Cancer Foundation, the guideline affirms that FLC is a biologically distinct cancer that requires specialized approaches to care.

The publication outlines consensus recommendations spanning diagnosis, surgery, locoregional and systemic therapies, as well as psychological and palliative care. It emphasizes the importance of molecular testing, aggressive surgical management when appropriate, and early participation in clinical trials. Together, these guidelines reflect both the current realities of FLC treatment and promising emerging advances, while underscoring the urgent need for continued research.

A “plain English” summary of the guidelines and frequently asked questions about them can be found here.

Upcoming webinar

To further explore the recommendations, FCF is hosting a panel discussion featuring several members of the expert team that authored the publication. Please join us on Tuesday, April 7, at 7:00 pm ET (4:00 pm PT) for a live Zoom webinar to learn more about this important effort.

Click here to register for the event.